Please login to the form below

SGLT2 inhibitor

This page shows the latest SGLT2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

Boehringer Ingelheim and Lilly’s SGLT2 inhibitor Jardiance (empagliflozin) was the first drug approved by the FDA as being able to reduce the risk of cardiovascular death in patients with type ... products. The LEADER trial of Victoza also showed a 13%

Latest news

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Janssen’s type 2 diabetes treatment is in a battle with rival drugs (especialy in its SGLT2 inhibitor class), where proof of cardiovascular benefits are now vital for future market share. ... The first SGLT2 inhibitor to gain this EU label update was
J&J’s Invokana aces diabetic kidney disease trial, setting up filings

Johnson &Johnson’s SGLT2 inhibitor Invokana worked so well in a trial involving diabetics with chronic kidney disease that the study has been halted early – potentially opening up a lucrative new ... risk of lower-limb amputation in diabetics,
J&J says real-world data finds no amputation risk for Invokana

A year ago, regulators slapped warnings to the labelling for Johnson &Johnson’s diabetes drug Invokana, setting it at a disadvantage against rival drugs in the SGLT2 inhibitor class, but now ... results show that the “overall benefit-risk profile of
PMCPA takes AZ to task over asthma drug press release

body. The source of GSK’s anger was a PR put out by AZ after interleukin-5 inhibitor Fasenra (benralizumab) was recommended for approval by the EMA’s Committee for Medicinal ... company in Amsterdam last November relating to SGLT2 inhibitor diabetes
FDA starts review of Sanofi’s oral type 1 diabetes drug

The drug is a dual inhibitor of SGLT1 and SGLT2 and is thought to work by reducing glucose absorption in the gastrointestinal tract and glucose reabsorption by the kidneys, as well ... The SGLT2-selective drugs are approved to date only for type 2

More from news
Approximately 1 fully matching, plus 64 partially matching documents found.

Latest Intelligence

China: AstraZeneca’s new engine for growth and innovation

One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
Medius Deal Watch table for March 2015

Company acquisition. Marketed BTK inhibitor for haematological cancers pipeline incl. 3 products in clinic. ... 165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.
Interview: Christopher Boulton, AstraZeneca

Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The deal gives
Pharma deals during April 2013

The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... Clearly the pressure is on, the announcement coming only a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

Pfizer appoints diabetes expert Morris Birnbaum

Pfizer's interests in the area include a collaboration with Merck &Co on the sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin to treat diabetes.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Medical Writer: Great salary and benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Project / Account Manager (Medical Education): Salary TBC

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Medical Writers Required – Cheshire: DOE

Senior Medical Writer: Competitive Salary

New Business Director - PR: Competitive Salary and benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Medical/ Scientific Director: Salary TBC

Senior Account Executive, London, Medical Communications: Excellent package

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Consultant Health Economics - London / Oxford: Negotiable

Scientific Director / Editorial Team Leader: Great salary and benefits

Events Manager – Med Comms – Surrey: Salary TBC

Associate Editorial Director – Med Comms – London: Salary TBC

Director, Market Access / HEOR - North-West: Negotiable

Senior Account Director development role to Business Director, H...: Excellent package

Account Director: £48, 000 - £60, 000

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Account Manager / Account Director: Competative

Client Services Director – Medical Education Agency – North West...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...